MA5-13705

antibody from Invitrogen Antibodies

Targeting: KRT10 CK10, K10, KPP

Provider product page for MA5-13705

Western blot

Immunohistochemistry

Flow cytometry

Other assay

Antibody data

Antibody Data
Antigen structure
References [48]
Comments [0]
Validations
Immunohistochemistry [1]
Flow cytometry [1]
Other assay [3]

Submit

Product number: MA5-13705 - Provider product page
Provider: Invitrogen Antibodies
Product name: Cytokeratin 10 Monoclonal Antibody (DE-K10)
Antibody type: Monoclonal
Antigen: Other
Description: MA5-13705 targets Cytokeratin 10 in IF, IHC (P), and WB applications and shows reactivity with Canine, Feline, Human, and Rat samples. The MA5-13705 immunogen is cytoskeletal preparation extracted from human ectocervical epithelium.
Reactivity: Human, Rat, Canine, Feline
Host: Mouse
Isotype: IgG
Antibody clone number: DE-K10
Vial size: 500 µL
Concentration: 0.2 mg/mL
Storage: 4° C

KRT10 protein structure - MA5-13705 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4 AVX001 inhibited proliferation in a stratified epithelium. HaCaT grown on porous collagen-coated membranes were maintained at the air-liquid interface for 12 days with exposure to exogenous EGF (1 ng/mL) in the absence or presence of AVX001 (5 µM). ( A ) PGE 2 levels measured in the supernatants at day 12 by ELISA. ( B - D ) Immunohistochemistry using anti-Ki-67 MIB1 (DAB+) and anti-cytokeratin (CK)10 (Permanent Red) antibodies with hematoxylin counterstain. Brightfield images were taken at 40X magnification and used to quantify ( B ) the thickness (stratification) of the cultures, ( C ) the proportion of proliferating cells (proliferation index = Ki-67-positive cells/total cells), and ( D ) the proportion of CK10-positive cells (CK10 index = CK10 positive cells/total cells.) Typically, >20 images were collected at 40X magnification per replicate, with data being the mean +- SEM for three replicates. Statistical significance was calculated by one-way ANOVA with Dunnett's post-analysis; * p < 0.05, ** p < 0.01, *** p < 0.005 versus vehicle-treated control. ( E ) Three representative images are shown for (i) vehicle and (ii) AVX001-treated cultures.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: FIGURE 6 Activation of actomyosin contractility induces epidermal differentiation of cSCC cells. (A) Whole-cell lysates of confluent A431 cells treated with or without 5 mug/ml RhoA activator (RhoA act.) for 24 h were immunoblotted for K5, K10, and beta-actin. Bar graphs show the result of the densitometric quantification of K5 and K10. Values were normalized with the mean values in control cells. Each bar represents mean +- SD. n = 3 independent experiments. * p < 0.05; ** p < 0.01. (B) Confluent A431 cells treated with 5 mug/ml RhoA activator (RhoA act. ), 100 muM p -aminoblebbistatin (Blebb) or combination of both drugs (RhoA act. + Blebb) for 24 h were stained for markers of basal (undifferentiated, K5, magenta) and suprabasal (differentiated, K10, cyan) keratinocytes. Cell nuclei were labeled with Hoechst 33342 (green). Scale bar, 50 mum. (C, D) Quantification of (B) . Fluorescence intensities of K5 (C) and K10 (D) in confluent A431 cells treated with indicated compounds for 24 h. Values were normalized with the mean values in control cells. Box-and-whisker plots show the median, the interquartile range, and the tenth and ninetieth percentiles. n = 60 fields of view from three independent experiments were pooled for the analysis. * p < 0.05; *** p < 0.001; NS, p > 0.05. (E, F) Quantification of fluorescence intensities of K5 (E) and K10 (F) in confluent A431 cells expressing control-shRNA or alpha-catenin-shRNA treated with indicated compounds for 24 h. Values were norma

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 Regulation of cPLA 2 /PGE/EP4 signaling by Th17 cytokines (A) Representative images showing immunostaining with anti-Ki-67 (DAB+) and anti-cytokeratin 10 (Permanent Red) antibodies. Scale bar, 10 muM. (B) Quantification of (i) the proportion of CK10 positive cells, (ii) the proportion of proliferating cells, and (iii) the thickness of the cultures. The data shown are the mean +- SEM for three replicates. One-way ANOVA followed by Dunnett's multiple comparison test was used to make statistical comparisons with either the untreated control (CTRL) or stimulated control (Vehicle), where ### indicates p < 0.001 versus CTRL (C) Eicosanoid levels measured by ELISA for (i) PGE 2 , (ii) 12s-HETE, and (iii) LTB 4 . Data shown are the mean +- SEM of three replicates, measured in duplicate. One-way ANOVA followed by Dunnett's multiple comparison test was used to compare the PGE 2 levels with either the untreated control (CTRL) or the stimulated control (Vehicle), where ### indicates p < 0.001 versus CTRL and *** indicates p < 0.001 versus Vehicle. (D) Heatmap of Log 10 fold changes in expression relative to unstimulated controls (CTRL) for genes involved in PGE 2 synthesis, degradation, and signaling. Data are the mean of three replicates. X indicates that expression was undetectable. (E) Schematic summary showing how Th17 cytokines could regulate PGE 2 release and activate downstream signaling events via the EP4 receptor. The gene expression of the components in red was increas